Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSH | P09668 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 6/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.41 |
| ▸ | F13A1 | P00488 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384105 | 0.97 | CXCR4 (0.45) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5369685 | 0.96 | CXCR4 (0.45) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5367237 | 0.96 | CXCR4 (0.48) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5384108 | 0.94 | CXCR4 (0.47) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5372278 | 0.93 | CCKBR (0.43) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5372281 | 0.90 | CXCR4 (0.45) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL5367473 | 0.89 | PTPN1 (0.41) | — | |
| SCHEMBL5367479 | 0.85 | F2 (0.42) | GLP1RGCGRGIPR | |
| SCHEMBL31191396 | 0.79 | CXCR4 (0.50) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29800522 | 0.78 | CXCR4 (0.51) | CXCR4CTSLCTSSCTSKCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169892-B2 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | ASTELLAS PHARMA INC. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1591450-A1 | CONJUGATE FOR RETENTION IN BLOOD AND CANCER TISSUE-SPECIFIC DRUG DELIVERY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050054026-A1 | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |